Michael Lyles
Psychiatry · Roswell, GANPI 1861567208
Payments from drug & device makers
Across 195 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$844
- AbbVie$638
- Axsome Therapeutics, Inc.$465
- Otsuka America Pharmaceutical, Inc.$423
- Takeda Pharmaceuticals U.S.A., Inc.$235
- Lundbeck LLC$210
- plus $419 from 9 others
What the payments were for
- Food & beverage$3,233100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 100 | $844 |
| AbbVie(2 entities) | 35 | $638 |
| Axsome Therapeutics, Inc. | 13 | $465 |
| Otsuka America Pharmaceutical, Inc. | 7 | $423 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $235 |
| Lundbeck LLC | 9 | $210 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $112 |
| Almatica Pharma LLC | 4 | $85 |
| Johnson & Johnson | 4 | $76 |
| Bausch Health US, LLC | 2 | $41 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Merck | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Corium, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,233 in reported general payments places this provider in the 80th percentile of 900 psychiatry providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AuvelityDextromethorphan Hbr/Bupropion | 49 | $61,504 |
| VraylarCariprazine Hcl | 13 | $23,280 |
| TrintellixVortioxetine Hydrobromide | 31 | $20,484 |
| VyvanseLisdexamfetamine Dimesylate | 14 | $11,446 |
| CymbaltaDuloxetine Hcl | 12 | $6,041 |
| Aripiprazole | 116 | $4,502 |
| Lisdexamfetamine Dimesylate | 11 | $4,185 |
| Bupropion XlBupropion Hcl | 143 | $3,665 |
| Duloxetine Hcl | 198 | $3,422 |
| DayvigoLemborexant | 11 | $2,990 |
| Mirtazapine | 213 | $2,895 |
| Bupropion Hcl SrBupropion Hcl | 177 | $2,853 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 60 | $2,843 |
| Clonazepam | 267 | $2,815 |
| Modafinil | 39 | $2,769 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Axsome Therapeutics, Inc.Auvelity | $465 | $61,50449 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $235 | $31,92945 claims |
| AbbVieVraylar | $638 | $23,28013 claims |
| Almatica Pharma LLCSertraline Hcl | $85 | $57987 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Roswell
- Michael RosenRoswell$141K
- Richard WinerRoswell$103K
- Joel KirsonRoswell$99K
- Alexandra DoddRoswell$54K
- Scot BayRoswell$26K
- Robert RiesenbergAtlanta$51.1M
- Saundra Maass-RobinsonAtlanta$11.1M
- David PurselleAtlanta$7.4M
- Maria JohnsonDecatur$5.4M
- Bethany DavisAtlanta$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.